Xspray granted additional product patents in the United States for HyNap-Sora and HyNap-Nilo

Regulatory press release 2019-06-11

STOCKHOLM – June 11, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) announces that the United States Patent and Trademark Office (USPTO) has granted Xspray two new patents in the United States for its product candidates HyNap-Sora and HyNap-Nilo. The new patents are Xspray’s sixth and seventh product patents, respectively, in the United States, which is Xspray’s main market. The new patents will expire January 11, 2033.

 “The new patents for HyNap-Sora and HyNap-Nilo make it significantly more difficult for our competitors to copy upcoming products from our unique platform technology. The patents are also essential for our ability to do good business deals and they strengthen our position in the US market,” says Per Andersson, CEO of Xspray.

The new patents, US 10,314,829 and US 10,314,830 respectively, cover the pharmaceutical compositions of the company's product candidates HyNap-Sora and HyNap-Nilo. Xspray is a product company with a broad portfolio of drug candidates in the same substance class that can be reformulated using the same technology platform.

At the end of 2018, Xspray was granted an additional patent for HyNap-Dasa for the US market. This patent, along with these two new ones, are strong and broad composition patents which relate to solid amorphous forms of the active substance. The original products for Dasatinib, Sorafinib and Nilotinib, had total US sales exceeding USD 2 billion in 2018.

For further information, please contact:

Per Andersson, CEO, Xspray Pharma AB
Mobile: +46 (0) 706 88 23 48
Email: per.andersson@xspray.com

This information is inside information that Xspray Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 11 a.m. CET on June 11, 2098.

About Xspray Pharma

Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development. Xspray uses its innovative, patented RightSize technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered 39 in 2018. The company’s leading product candidates, HyNap-Dasa, HyNap-Sora and HyNap-Nilo, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively. The launch of the first product candidate, HyNap-Dasa, is planned to take place in 2021. The substance patent for the original drug Sprycel® (dasatinib) expires at the end of 2020, and the secondary patents in 2026, which offers Xspray’s HyNap-Dasa a period of five years of semi-exclusivity before other competitors gain access to the market.

The company has patented manufacturing technology, equipment and the resulting products. The shares in Xspray Pharma are traded on Nasdaq First North Stockholm.

www.xspraypharma.com

Redeye AB is Xspray Pharma’s Certified Adviser
certifiedadviser@redeye.se
Telephone: +46 (0) 8 121 576 90